The Many Faces of Silybum marianum (Milk Thistle): Part 2-Clinical Uses, Safety, and Types of Preparations

Alternative and Complementary Therapies

Volumn 9, Issue 5, 2003, Pages 251-256

  Abascal, Kathy ^a,b   Yarnell, Eric ^a,b  

^a Botanical Medicine Academy ^*

^b Botanical Medicine Academy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIRETROVIRUS AGENT; BUTYROPHENONE; CHLORZOXAZONE; COUMARIN ANTICOAGULANT; DIMETHYL SULFOXIDE; DOXORUBICIN; ERYTHROMYCIN; GLUCOSE; HEMOGLOBIN A1C; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDINAVIR; INDOMETACIN; INSULIN; MEPHENYTOIN; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOTHIAZINE; PLANT EXTRACT; PROTEINASE INHIBITOR; SILIBININ; SILICRISTIN; SILIDIANIN; SILYBUM MARIANUM EXTRACT; SILYMARIN; TACRINE; UNINDEXED DRUG; WARFARIN;

ALCOHOL LIVER CIRRHOSIS; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL MODEL; ANTICHOLINERGIC EFFECT; ANTIINFLAMMATORY ACTIVITY; BILE DUCT OBSTRUCTION; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG FORMULATION; DRUG SAFETY; FETAL ALCOHOL SYNDROME; FETUS; HERBAL MEDICINE; HUMAN; HUMAN CELL; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY DISEASE; LD 50; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALARIA; MENTAL DISEASE; MOUSE; NAUSEA; NERVE CELL CULTURE; NEUROPROTECTION; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; SIDE EFFECT; SILYBUM MARIANUM; THALASSEMIA MAJOR; VIRUS INFECTION;

EID: 0142151114     PISSN: 10762809     EISSN: None     Source Type: Journal    
DOI: 10.1089/107628003322490698     Document Type: Review

References (51)

1. Velussi M, Cernigoi AM, De Monte A, et al. Long-term (12 months) treatment with an anti-oxidant drug (silymarin) and its effect on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients. J Hepatol 1997;26:871-879.
2. Velussi M, Cernigoi AM, Viezzoli L, et al. Silymarin reduces hyperinsulinemia, malondialdehyde levels and daily insulin need in cirrhotic diabetic patients. Curr Ther Res 1993;53:533-545.
3. Schonfeld JV, Weisbrod B, Muller MK. Silybinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporine A toxicity. Cell Mol Life Sci 1997;53(11-12):917-920.
4. Soto PC, Sanchez RM, Uria CE, Favari PL. Silymarin effect in the pancreas of alloxan-induced diabetes mellitus in the rat [in Spanish].Rev Mex Ciencia Farm 2002;33:5-10.
5. Soto CP, Perez BL, Favari LP, Reyes JL. Prevention of alloxan-induced diabetes mellitus in the rat by silymarin. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998;119:125-129.
6. Gorio A, Donadini ML, Finco C, et al. Alterations of protein mono-ADP-ribosylation and diabetic neuropathy: A novel pharmacological approach. Eur J Pharmacol 1996;311:21-28.
7. Donadoni ML, Gavezzotti R, Borella F, et al. Experimental diabetic neuropathy: Inhibition of protein mono-ADP-ribosylation prevents reduction of substance P axonal transport. J Pharmacol Exp Ther 1995;274:570-576.
8. Wang MJ, Lin WW, Chen HL, et al. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. Eur J Neurosci 2002;16:2103-2112.
9. Kang JS, Jeon YJ, Kim HM, et al. Inhibition of inducible nitric-oxide synthase expression by silymarin in lipopolysaccharide-stimulated macrophages. J Pharmacol Exp Ther 2002;302:138-144.
10. Kittur S, Wilasrursmee S, Pedersen WA, et al. Neurotrophic and neuroprotective effects of milk thistle (Silybum marianum) on neurons in culture. J Mol Neurosci 2002;18:265-269.
11. Mazzio WA, Harris N, Soliman FKA. Food constituents attenuate monamine oxidase activity and peroxide levels in C6 astrocyte cells. Planta Med 1998;64:603-606.
12. Rui YC. Advances in pharmacological studies of silymarin. Memorias do Instituto Oswaldo Cruz 1991;86(suppl.2):79-86.
13. Mitchell WA Jr. Plant Medicine in Practice. St. Louis: Churchill Livingstone, 2003.
14. Busby A, La Grange L, Edwards J, King J. The use of silymarin/phospholipids compound as a fetoprotectant from ethanol-induced behavioral deficits. J Herbal Pharmacother 2002;2:39-47.
15. Reid C, Edwards J, Wang M, et al. Prevention by a silymarin/ phospholipids compound of ethanol-induced social learning deficits in rats. Planta Med 1999;65:421-424.
16. La Grange L, Wang M, Watckins R, et al. Protective effects of the flavonoid mixture, silymarin, on fetal rat brain and liver. J Ethnopharmacol 1999;65:53-61.
17. Edwards J, La Grange L, Wang M, Reyes E. Fetoprotectivity of the flavanolignan compound siliphos against ethanol-induced toxicity. Phytother Res 2000;14:517-521.
18. Johnson VJ, He Q, Osuchowski MF, Sharma RP. Physiological responses of a natural antioxidant flavonoid mixture, silymarin, in BALB/c mice: III. Silymarin inhibits T-lymphocyte function at low doses but stimulate inflammatory processes at high doses. Planta Med 2003;69:44-49.
19. Gupta OP, Sing S, Bani S, et al. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipooxygenase. Phytomedicine 2000;7:21-24.
20. De la Puerta R, Martinez E, Bravo L, Ahumada MC. Effect of silymarin on different acute inflammation models and on leukocyte migration. J Pharm Pharmacol 1996;48:968-970.
21. Saliou C, Rhin B, Cillard J, et al. Selective inhibition of NF-kappa-B activation by the flavonoid hepatoprotector silymarin in HepG2: Evidence for different activating pathways. FEBS Lett 1998;440(1-2):8-12.
22. Dehmlow C, Erhard J, De Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silybinin. Hepatology 1996;23:749-754.
23. Fiebrich F, Koch H. Silymarin, an inhibitor of lipoxygenase. Experientia 1979;35:1548-1550.
24. Fiebrich F, Koch H. Silymarin, an inhibitor of prostaglandin synthetase. Experientia 1979;35:1550-1552.
25. Passera D, Fragasso A, Orlando R, et al. Effect of silybinin on biliary lipid composition: Experimental and clinical study. J Hepatol 1991;12:290-295.
26. Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000;32:897-900.
27. Wellington K, Jarvis B. Silymarin: A review of its clinical properties in the management of hepatic disorders. Biodrugs 2001;15:465-489.
28. Reyes H. The spectrum of liver and gastrointestinal disease seen in cholestasis of pregnancy. Gastroenterol Clin North Am 1992;21:905-921.
29. Hagymasi K, Kocsis I, Lugasi A, et al. Extrahepatic biliary obstruction: Can silymarin protect liver function? Phytother Res 2002;16(suppl.1): S78-S80.
30. Gonzalez Correa JA, De la Cruz JP, Gordillo J, et al. Effects of silymarin MZ-80 on hepatic oxidative stress in rats with biliary obstruction. Pharmacology 2002;64:18-27.
31. Crocenzi FA, Sanchez-Pozzi EJ, Pellegrino JM, et al. Beneficial effects of silymarin on estrogen-induced cholestasis in the rat: A study in in vivo and in isolated hepatocyte couplets. Hepatology 2001;34:329-339.
32. Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia 1995;66:3-42.
33. Fraschini F, Demartini G, Esposti D. Pharmacology of silymarin. Clin Drug Invest 2002;22:51-65.
34. Dvorak Z, Kosina P, Walterova D, et al. Primary cultures of human hepatocytes as a tool in cytotoxicity studies: Cell protection against model toxins by flavonolignans obtained from Silybum marianum. Toxicol Lett 2003;137:201-212.
35. Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994;91:51-63.
36. Palaciano G, Portincasa P, Palmier V, et al. The effect of silymarin on plasma levels of malon-dialdehyde in patients receiving long-term treatment with psychotropic drugs. Curr Ther Res Clin Exp 1994;55:537-545.
37. Fintelmann V. Serumcholinesterase and other liver enzymes in postsurgical conditions [in German]. Med Klin 1973;68:809.
38. Allain H, Schück S, Lebreton S, et al. Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease. Dement Geriatr Cogn Disord 1999;10:181-185.
39. Zuber R, Modriansky M, Dvorak Z, et al. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002;16:632-638.
40. Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphobluduronosyl transferase in human hepatocyte cultures. Drug Metab Disp 2000;28:1270-1273.
41. Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002;32:451-478.
42. Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002;22:551-556.
43. Zhao J, Agarwal R. Tissue distribution of silybinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis 1999;20:2101-2108.
44. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silybinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000;86:250-256.
45. Miguez MP, Anundi I, Sainz-Pardo LA, Lindros KO. Hepatoprotective mechanism of silymarin: No evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994;91:51-63.
46. Comoglio A, Tomasi A, Malandrino S, et al. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol 1995;50:1313-1316.
47. Raskovic A, Jakovljevic V, Popovic M, et al. Effect of methoxsalen and an infusion of Silybum marianum on enzymes relevant to liver function. Pharmaceut Biol 2002;40:70-73.
48. Samykina LN, Sheshunov IV, Gil'miyarov EM. Bioactive addition from Silybum marianum in solving healthcare problems [in Russian]. Voprosy Pitaniya 1998;Vol.0(3):33-35.
49. Khan SA, Kahlid L, Rauf MA, et al. Biological evaluation of Silybum marianum seed oil for nutritional purposes. Pakistan J Sci Ind Res 1986;29:430-434.
50. Pandey GP, Srivastava DN. Therapeutic efficacy of some indigenous preparations against paracetamol induced liver damage in rabbits. Ind Vet Med J 1993;17:14-17.
51. Sincholle D. Study of the in vivo antiradical effect of an extract of seeds of the milk thistle [in French.]. Plantes Med Phytother 1988;22:119-123.